Open AccessTreatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report and Brief Review
Author(s) -
Y. B. Zhao,
Yong Cao,
Xiuyu Wang,
Tianyi Qian
Publication year - 2022
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s353743
Subject(s) - toxic epidermal necrolysis , medicine , maculopapular rash , rash , skin biopsy , adverse effect , methylprednisolone , dermatology , gallbladder , gastroenterology , biopsy
Sintilimab is a fully human monoclonal antibody targeting PD-1, which has been considered well tolerated among patients and widely applied in malignancies.